Koby Evans Faces Charges After Indictment Alleges He Helped Funnel Patients to Leigh Tesar for Medicare Billing

Federal prosecutors say Evans participated in alleged pay-for-patient kickback arrangements connected to costly wound allografts, while the pending criminal case distinguishes his alleged referral conduct from the substantive health care fraud counts filed against Tesar.

WASHINGTON, DC, August 22, 2026 — Koby Evans faces two federal charges after prosecutors accused the Apollo Beach registered nurse of helping direct Medicare beneficiaries toward Leigh Tesar for expensive wound-allograft treatment and receiving compensation allegedly calculated from the resulting business.

The June 2026 indictment presents Evans as a purported product representative whose practical value allegedly came from locating patients with wounds, introducing them into Tesar’s treatment operation, and sharing financially in allograft transactions ultimately billed through Medicare.

Prosecutors say that arrangement formed one segment of a wider operation that generated more than $118 million in Medicare claims during approximately eighteen months, producing more than $61 million in payments to Tesar and her Primecare practice.

Evans’s alleged participation is illustrated through several communications and one representative bank transfer, including a January introduction mentioning prospective patients, a product-price calculation, a later warning about discussing money, and an August payment of approximately $10,998.

Those allegations are serious, but Evans is not named in the five substantive health care fraud counts brought exclusively against Tesar, meaning his charged conduct and potential responsibility must be assessed separately from every disputed treatment or claim.

Evans has pleaded not guilty, remains presumed innocent, and may challenge whether the government can prove an unlawful agreement, a prohibited referral purpose, his knowing and willful participation, and the meaning of each disputed payment or communication.

Who Koby Evans Is in the Federal Case

The federal indictment filed in the Middle District of Florida identifies Evans as a Hillsborough County resident and licensed registered nurse, while public reporting describes the thirty-one-year-old defendant as residing in Apollo Beach near Tampa.

The charging document also identifies Evans as an owner of Healing His Way, a Florida limited liability company whose Bank of America account allegedly received the representative transfer underlying his individual federal kickback-receipt criminal charge.

Company-I, an unnamed Pennsylvania business that marketed and sold wound-care products to Tesar and Primecare, allegedly operated under a fictitious name and engaged Evans, Walter Presha Junior, and others as purported independent allograft sales representatives.

Neither owning a nursing business nor working as a product representative is inherently unlawful, because clinicians, suppliers, educators, marketers, and independent contractors routinely participate in legitimate health care commerce under carefully structured compensation arrangements.

The government instead alleges that the written or apparent sales relationship was a sham whose true economic purpose was to pay Evans for Medicare patient referrals, an accusation requiring evidence about actual services, compensation methods, communications, and patient movement.

How the Alleged Patient Funnel Began

Prosecutors describe January 6, 2025, as an important starting point, when Tesar allegedly introduced Evans by text message to an owner of Company-I and emphasized that he already had several prospective patients who could begin treatment quickly.

That introduction may become central evidence because it connected Evans’s anticipated commercial role with people potentially eligible for wound care before the indictment’s later communications described a percentage calculation tied to an expensive allograft product.

The government will likely argue that the wording presented Evans primarily as a source of patients rather than an ordinary product salesperson who cultivated provider accounts, explained clinical features, coordinated inventory, or supported applications after independent treatment decisions.

Defense counsel may answer that health care professionals commonly know patients needing specialized services and that mentioning prospective cases does not prove compensation was requested, offered, received, or understood as payment for referrals rather than lawful work.

The indictment does not publicly identify the prospective patients discussed during that introduction, describe their wounds, explain how Evans knew them, or establish whether every person then contemplated ultimately received an allograft from Tesar’s practice.

Those missing details may emerge through discovery, because patient charts, communications, calendars, facility records, testimony, and claims data could either connect the introduction to reimbursed treatment or materially weaken the government’s proposed evidentiary sequence.

A Twenty-Percent Formula Draws Prosecutorial Attention

On January 27, 2025, Tesar allegedly told Evans that a new product cost $2,000 per square centimeter and explained that his twenty-percent share would be calculated from that amount instead of $1,591.

The charging document says Tesar initially described the $2,000 figure as reimbursement before correcting herself and calling it product cost, a distinction that may require testimony concerning invoices, acquisition terms, Medicare payment rules, and distributor accounting.

Prosecutors may characterize the exchange as unusually direct evidence that Evans’s compensation rose with the price and quantity of allografts used on patients he supplied, creating a personal financial incentive favoring more costly wound treatment.

Evans may contend that percentage-based compensation reflects lawful sales activity and that the government must prove what services his business actually provided, what the contract required, and whether payments depended on patient referrals rather than legitimate product support.

The difference between twenty percent of $2,000 and twenty percent of $1,591 becomes substantial when multiplied across many square centimeters, helping explain why a brief pricing discussion can take on outsized importance in a high-value wound-care prosecution.

Price awareness alone does not establish criminal intent, however, because nurses and sales representatives may legitimately discuss acquisition costs, reimbursement constraints, product performance, inventory availability, wastage, coverage policies, and commercial compensation without purchasing patient access.

The April Message and an Alleged Effort at Concealment

The indictment next highlights an April 21, 2025, exchange that allegedly followed discussion about the amount and timing of anticipated payments, after which Tesar warned Evans that she was not supposed to discuss money with the representatives.

Federal prosecutors may present that warning as evidence that participants understood the financial arrangement required deliberate concealment, especially when combined with the earlier percentage formula and the later patient-linked transaction accounting transmitted directly to Company-I.

The defense may argue that a statement authored by Tesar principally reveals her own concerns, not Evans’s knowledge, agreement, or intentions, unless surrounding messages establish that he understood and accepted the unlawful meaning prosecutors assign.

Context will therefore matter greatly, including what Evans said before and after the warning, whether any messages are missing, how the parties ordinarily communicated, and whether compliance restrictions or contractual boundaries offered a lawful explanation.

Electronic evidence must also be authenticated and presented accurately, because screenshots, exported conversations, device extractions, account records, and witness recollections can create disputes over authorship, completeness, timing, interpretation, and whether informal language reflected an actual agreement.

Patient-Level Accounting Allegedly Preceded Payment

On July 22, 2025, Tesar allegedly emailed a Company-I owner with information matching Primecare payments to particular allografts, patients, and purported representatives, including Evans, to ensure corresponding compensation was issued.

Prosecutors may use that email as a bridge connecting abstract pricing discussions with specific beneficiaries and transactions, because it allegedly mapped money received by Primecare back to products, patients, and the representatives associated with them.

If the accounting shows that compensation depended directly upon identified patients and paid claims, the government may argue that the distributor served as a financial intermediary converting Medicare-funded wound treatment into deliberately disguised referral payments.

Evans can challenge whether the email accurately described his work, whether he received or knew about it, whether patient identifiers were used for legitimate sales-credit allocation, and whether Company-I independently determined compensation under lawful agreements.

The identity and testimony of Company-I personnel could become pivotal, since they may explain why Evans was recruited, what services were expected, how sales credit was assigned, who authorized payments, and whether referrals controlled the calculation.

The $10,998 Transfer Underlying Count Ten

Prosecutors allege that on August 15, 2025, Company-I transferred approximately $10,998 into the Healing His Way account, representing a kickback for Evans referring a Medicare beneficiary to Tesar for allografts billed to the federal program.

Count Ten charges Evans with knowingly and willfully soliciting and receiving remuneration in return for that referral, while Count Eight separately charges Tesar with causing the corresponding payment through Company-I to induce federally reimbursable wound-care business.

One bank transfer can therefore support charges on opposite sides of an alleged kickback transaction, although prosecutors must prove the required purpose and knowledge separately for the alleged payer and recipient rather than relying upon money movement alone.

A deposit establishes that funds entered an account, but its legal significance depends upon why the payment was made, what work supported it, what Evans understood, and whether referral of a Medicare beneficiary formed the prohibited bargain.

The indictment does not publicly name the beneficiary associated with Evans’s charged transfer, state the precise allograft quantity involved, or specify the amount Medicare billed and paid for that individual’s related course of wound treatment.

That patient-level evidence may determine whether the transfer reflects legitimate services, a sales commission, or the government’s alleged pay-for-patient model, making records from Primecare, Company-I, Healing His Way, and Medicare especially important in litigation.

Why $10,998 Is Not the Entire Financial Allegation

The forfeiture section attributes approximately $263,223 in alleged offense proceeds to Evans, a figure far larger than the $10,998 representative transfer identified in Count Ten and therefore dependent upon additional tracing evidence beyond that single deposit.

Prosecutors may attempt to connect other payments or assets with the charged conspiracy, while Evans and affected third parties may contest source, ownership, valuation, traceability, legitimate revenue, and whether particular property legally qualifies as forfeitable proceeds.

The $263,223 amount remains an allegation rather than a judgment, and the government’s request for forfeiture does not establish that every dollar entering Healing His Way came from referrals or that Evans personally retained every disputed payment.

Federal forfeiture rules may permit substitute property when directly traceable assets become unavailable under specified conditions, but any final order would require a conviction, legal findings, and proof connecting recoverable value to covered criminal conduct.

The difference between the charged transfer and requested forfeiture also offers defense counsel an opportunity to demand a transaction-by-transaction explanation instead of allowing the case’s broader Medicare totals to substitute for individualized proof against Evans.

Two Charges, Not the Entire Indictment

Count Six alleges that Evans, Tesar, Presha, and others knowingly joined a conspiracy between approximately May 2024 and November 2025 to defraud the United States and to offer, pay, solicit, and receive health care kickbacks.

Under that theory, the agreement allegedly impaired federal oversight, generated allograft claims from purchased referrals, concealed compensation, enriched participants, and diverted proceeds for personal financial benefit or to continue the unlawful conspiracy.

Conspiracy can be proved through circumstantial evidence, but professional association, parallel conduct, patient coordination, a business contract, or receipt of money does not automatically demonstrate that Evans knowingly and voluntarily embraced an unlawful common objective.

Count Ten is narrower because it focuses upon the August 2025 transfer and requires proof that Evans knowingly and willfully solicited or received remuneration in return for referring a beneficiary for federally payable wound-care products or services.

Evans is not charged in Counts One through Five, which identify representative Medicare claims and accuse Tesar of substantive health care fraud, nor is he charged in Counts Seven and Eight, which address Tesar’s alleged payment conduct.

Jurors would therefore need to separate evidence by defendant and count, deciding whether Evans committed the two offenses charged against him without automatically transferring responsibility from Tesar’s disputed clinical records, procedures, billing, or personal expenditures.

Why Allograft Economics Matter

The products involved are bioengineered skin substitutes, including some derived from human placental tissue, that may legitimately assist healing when a qualifying wound, documented conservative care, patient condition, and applicable Medicare requirements support their use.

Medicare reimbursement can become exceptionally large because certain products carry substantial per-square-centimeter prices, meaning wound dimensions, repeated applications, product selection, and documented wastage can dramatically affect both individual claim values and overall distributor or supplier revenue.

The indictment says relevant coverage rules required documented improvement, accepted treatment standards, attention to factors affecting healing, and appropriate conservative care before covered skin-substitute use for specified diabetic foot and venous leg ulcers generally occurred.

Prosecutors accuse Tesar of applying allografts without adequate conservative treatment, using them on infected or nonresponsive wounds, treating terminally ill patients whose wounds allegedly could not heal, and choosing products solely to maximize financial profit.

Those clinical accusations explain the government’s larger theory, but they do not independently prove Evans knew any identified treatment was unnecessary, that any application never occurred, or that any patient chart contained deliberately false medical information.

The government may seek to infer knowledge from his nursing background, communications, patient contacts, and compensation, while the defense may emphasize that Tesar or other professionals controlled clinical eligibility, documentation, product application, and billing decisions.

The Broader Medicare Billing Narrative

Federal authorities allege that Tesar and others submitted more than $118 million in claims for products and services that were medically unnecessary, ineligible, misrepresented, not performed, or procured through illegal kickbacks, generating over $61 million in payments.

The five substantive fraud counts list selected claims totaling approximately $3.96 million billed and approximately $2.82 million paid, yet none names Evans as a defendant or expressly assigns his referral activity to a particular representative claim.

That limitation does not prevent prosecutors from presenting broader evidence relevant to the conspiracy, but it requires careful reporting because Evans should not be described as personally submitting every claim or performing every disputed procedure without supporting proof.

The indictment also alleges that Tesar and others falsified records, claimed services never rendered, misstated prior treatment, backdated wound documentation, and altered patient-condition descriptions to support allograft coverage, serious accusations that remain untested at trial.

Evans’s defense may argue that he lacked access to billing systems or final charts, while prosecutors may examine whether messages, patient involvement, sales records, clinical experience, or payment calculations demonstrate awareness of irregular treatment or claims.

The ultimate analysis must remain individualized, because participation in an unlawful referral arrangement, if proven, would not necessarily establish responsibility for every false statement, while ignorance of billing details would not automatically defeat a properly proved kickback charge.

Beneficiary Inducements Require Precise Attribution

The indictment broadly alleges that Tesar, purported representatives including Evans and Presha, and others encouraged beneficiaries to start or continue allograft treatment through misrepresented costs, unlawful copayment waivers, free medical supplies, jewelry, and a leather recliner.

However, the public charging narrative does not identify which defendant allegedly supplied each benefit, spoke with each affected patient, approved each disputed waiver, or connected a particular inducement directly with Evans’s representative disputed bank transfer.

Responsible coverage should therefore avoid stating that Evans personally provided jewelry, furniture, supplies, or misleading cost information unless discovery, testimony, receipts, communications, or later court findings establish that specific conduct with sufficiently reliable individualized evidence.

The government may introduce more detailed patient evidence showing what beneficiaries were told and by whom, while the defense may argue that assistance addressed genuine medical or financial needs, followed lawful policy, or occurred without Evans’s knowledge.

Patients who recognize disputed services on Medicare statements can compare claim dates with calendars, caregiver notes, photographs, facility records, and treatment memories, then request clarification without discontinuing medically necessary wound care solely because another provider was indicted.

Evidence Likely to Decide the Case Against Evans

Prosecutors may assemble messages, phone records, contracts, invoices, calendars, facility-access information, patient communications, distributor files, product orders, bank statements, tax records, claims data, and witness testimony into a detailed chronological account of Evans’s alleged role.

The strongest government presentation would connect a beneficiary known to Evans with a referral to Tesar, an allograft application, a paid Medicare claim, distributor revenue, patient-linked accounting, and corresponding financial compensation entering Healing His Way.

Defense lawyers may look for broken links within that chain, including patients independently referred by others, legitimate services performed, inaccurate sales attribution, payments unrelated to federal business, ambiguous wording, incomplete message collections, or mistakes by Company-I.

They may also compare Evans’s contract with actual work records, asking whether he trained providers, coordinated products, maintained accounts, performed clinical support, or generated legitimate nonreferral value consistent with the amount and timing of compensation.

Prosecutors, conversely, may argue that lawful-looking paperwork cannot protect a sham arrangement when patient identities, claim payments, percentage formulas, concealed discussions, and account transfers collectively reveal that referrals supplied the true underlying compensated commercial service.

Because intent is rarely documented through an explicit confession, jurors may be asked to infer Evans’s understanding from the combined pattern, while remaining obligated to reject suspicion when evidence does not satisfy the criminal burden.

Bond Release and Evans’s Not-Guilty Plea

Independent Business Observer reporting on the Tampa Bay health care cases says Evans was arrested on June 18, 2026, and released that day on a $100,000 bond, alongside separately bonded co-defendants Tesar and Presha.

Court materials indicate that Evans later waived his personal appearance for arraignment and entered a not-guilty plea on July 7, 2026, preserving his right to discovery, motions, evidentiary challenges, witness confrontation, and a federal trial.

Bond is a pretrial compliance mechanism rather than a fine, acquittal, or finding about the evidence, and the stated amount does not measure guilt, anticipated punishment, restitution, forfeiture exposure, or relative responsibility among individual defendants.

Release permits Evans to assist counsel and prepare outside custody while remaining subject to court-ordered conditions, whose specific terms should not be invented from abbreviated docket summaries when the full operative order is not publicly described.

The not-guilty plea means both charged counts remain fully contested, placing the burden entirely upon prosecutors to prove every required statutory element beyond reasonable doubt through admissible evidence rather than indictment language or prejudicial publicity.

Professional and Reputational Consequences

Because Evans is identified as a registered nurse and business owner, the indictment may prompt licensing review, employer scrutiny, payer questions, banking concerns, and contracting difficulties governed by procedures separate from the federal criminal case.

Regulators and employers may apply lawful reporting and patient-safety obligations, but an unresolved indictment should not be presented as established professional misconduct when no guilty plea, trial verdict, or final disciplinary finding has resolved the allegations.

Search engines and compliance databases can preserve dramatic accusations long after their first publication, creating enduring consequences for employment, credit, insurance, vendor relationships, professional credentials, and community standing before federal litigation produces a definitive outcome.

The Amicus International Consulting news and analysis hub follows health care fraud, asset seizure, identity, extradition, and cross-border enforcement matters while maintaining the essential legal distinction among accusations, guilty pleas, convictions, settlements, dismissals, and acquittals.

Professionals confronting prolonged public attention may also review Amicus International Consulting’s crisis communications and reputation-management guidance, which emphasizes verified facts, coordinated stakeholder messaging, careful media preparation, and respect for active investigations, patients, witnesses, and courts.

Responsible communications can correct factual errors and explain procedural developments, but they must never conceal evidence, improperly influence testimony, intimidate beneficiaries, coordinate false accounts, obstruct investigators, or interfere with defense counsel’s legitimate federal litigation strategy.

A Case Within the 2026 National Takedown

The prosecution emerged from the Justice Department’s 2026 National Health Care Fraud Takedown, which announced charges against 455 defendants across fifty-six federal districts involving more than $6.5 billion in alleged false health care claims.

Federal officials said the nationwide operation included ninety doctors and other licensed medical professionals and generated seizures exceeding $182 million, reflecting expanded use of claims analytics, traditional investigation, financial tracing, and coordinated federal criminal enforcement.

Wound-care prosecutions have attracted particular attention because high per-square-centimeter product prices can produce extraordinary reimbursement, while fragmented relationships among distributors, marketers, clinicians, facilities, and billers can obscure individual responsibility until detailed transactional records are integrated.

The national scale provides important enforcement context, but it cannot relieve prosecutors of the burden of proving Evans’s own knowledge and conduct by substituting statistics, unrelated defendants, government rhetoric, or Tesar’s separate charges for individualized evidence.

What Happens Next for Koby Evans

The case may proceed through extensive discovery, motions involving electronic evidence, expert analysis, forfeiture disputes, plea negotiations, scheduling changes, evidentiary hearings, or trial as both sides reconstruct complicated individual patient, product, and payment histories.

Prosecutors will likely try to connect Evans’s prospective patients, the twenty-percent calculation, Tesar’s warning about money discussions, the July accounting email, and the August deposit into one coherent, chronological, financially integrated pay-for-patient referral narrative.

Defense counsel will likely test whether those events prove an unlawful agreement or instead combine lawful patient coordination, legitimate sales activity, another person’s statements, ambiguous compensation, and retrospective assumptions drawn from an unusually profitable wound-care business.

The most important unresolved questions concern which patients Evans allegedly referred, what services Healing His Way actually delivered, how Company-I calculated compensation, what Evans understood about Tesar’s billing, and how prosecutors derived the larger forfeiture figure.

Until a guilty plea, verdict, dismissal, or other binding resolution determines the outcome, Koby Evans remains presumed innocent of allegations that he converted access to Medicare beneficiaries into paid referrals supporting Tesar’s high-value allograft billing operation.